Publications by authors named "Frenz Ohm"
Article Synopsis
- The study aimed to fill the gap in understanding the epidemiology and healthcare of hyperhidrosis (HH) in Germany, using claims data from a health insurance provider between 2016 and 2020.
- In 2020, 0.70% of insured adults had a confirmed diagnosis of HH, with most cases being unspecified and localized forms more common in younger individuals, while generalized forms were more prevalent in older adults.
- The study highlights the need for more comprehensive data analysis, as severe cases and inpatient treatments for HH were rare, and care was predominantly managed by general practitioners.
Background: Topical agents are an essential component of psoriasis therapy.
Objectives: To develop a new version of the patient-reported Patient Benefit Index assessing the importance and achievement of treatment goals in topical psoriasis therapy in adult patients (PBI-TOP).
Methods: Through semi-structured interviews, focus groups and free-text questionnaires, patients reported their needs in topical treatment.
Innate immunity not only shapes the way epithelial barriers interpret environmental cues but also drives adaptive responses. Therefore, modulators of innate immune responses are expected to have high therapeutic potential across immune-mediated inflammatory diseases. IRAK4 is a kinase that integrates signaling downstream of receptors acting at the interface between innate and adaptive immune responses, such as Toll-like receptors (TLRs), interleukin-1R (IL-1R), and IL-18R.
View Article and Find Full Text PDFArticle Synopsis
- * A study analyzed 94 patients who switched from ADAO to ABP 501, and found that 33.3% experienced adverse events (AEs) or loss of response (LoR) within 12 to 14 weeks after the switch.
- * The findings suggest that switching from ADAO to ABP 501 significantly impacts treatment effectiveness, indicating that such switches should be carefully considered, especially for patients maintaining remission.